Viking Therapeutics, Inc. (VKTX) closed at $67.10 in the latest trading session, marking a +0.55% move from the prior day.
Vous n'êtes pas connecté
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
Viking Therapeutics, Inc. (VKTX) closed at $67.10 in the latest trading session, marking a +0.55% move from the prior day.
LEHI, Utah., Sept. 12, 2024. Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the...
Viking Therapeutics, Inc. (VKTX) reachead $58.10 at the closing of the latest trading day, reflecting a -0.5% change compared to its last close.
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street...
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $54.78, signifying a +1.2% move from its prior day's close.
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $54.78, signifying a +1.2% move from its prior day's close.
Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.
Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.
WEDNESDAY, Sept. 11, 2024 -- An experimental weight-loss pill appears to help people quickly shed pounds, a new study says. People who took the drug...
The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high...